WO1994018237A1 - Novel peptide having receptor activity and dna coding for said peptide - Google Patents
Novel peptide having receptor activity and dna coding for said peptide Download PDFInfo
- Publication number
- WO1994018237A1 WO1994018237A1 PCT/JP1994/000202 JP9400202W WO9418237A1 WO 1994018237 A1 WO1994018237 A1 WO 1994018237A1 JP 9400202 W JP9400202 W JP 9400202W WO 9418237 A1 WO9418237 A1 WO 9418237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- receptor
- dna
- gtp
- cdna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Definitions
- Novel peptides having receptor activity and DNA encoding the peptides
- the present invention relates to a novel peptide having a receptor activity coupled to a GTP-binding protein, which is used for, for example, treatment of a disease and development of a medicament, and a DNA encoding the peptide.
- animal cells respond to a primary messenger that acts on cells from outside the cell, such as neurotransmitters, hormones, or watercoils, and responds to that information. It has the function of performing physiological responses to Most of this primary messenger binds to receptors, which are specific glycoproteins located on the surface of cell membranes and directed outward.
- receptors which are specific glycoproteins located on the surface of cell membranes and directed outward.
- an intracellular enzyme hereinafter referred to as an effector
- a secondary information transmitter that is sent out into the cell from the intracellular enzyme is generated, and a physiological response corresponding to the secondary information transmitter is performed.
- an effector an intracellular enzyme
- a guanine nucleotide-binding control protein (hereinafter, referred to as a GTP-binding protein) that transmits a stimulus received by the receptor to the effector due to the binding of the primary messenger to the receptor. It has been shown to intervene.
- the GTP-binding protein usually exists as a guanine nucleosidonilate (hereinafter referred to as GDP) -bound form that is inactive against the effector.
- GDP guanine nucleosidonilate
- the receptor to which the primary messenger is bound promotes the dissociation of GDP bound to this inactive GTP binding protein.
- the GTP-binding protein from which GDP has been dissociated binds to GTP and ⁇ Mg + ion present in excess in the cell, and is converted to an active form. This active form of the GTP-binding protein activates the effector.
- the GTP-binding protein acting in this manner consists of three subunits, ⁇ , ⁇ , and 7.
- G D ⁇ binding inactive form It exists as a ⁇ 7-associated form, and in the GTP-binding form, it is present. And ⁇ ⁇ .
- ⁇ subunits include (1) those that control the enzymatic action involved in the production of secondary signaling substances, (2) those that control the opening and closing of the channel, Etc. have been confirmed.
- Examples of the former are those that activate adenylate cyclase ( ⁇ s ) or those that inactivate it.
- Subunit activating (C.q) isostatic 5 'is known. Examples of the latter include a subunit that has the effect of opening the K + channel, and an effect that closes the Ca 2 + channel when present in a large amount in nerve cells. Subunits ( 0. ) etc. are known.
- the effects of the /? 7 subunit on effectors include (1) activation of adenylate cyclase, (2) opening of K + channel, and And (3) activation of phospholipase C has been reported.
- Polypeptide 'sex holmon' receptor Neurokinin: Ne-char — ( Nature ) 329, 836-838 (1987), Endoselin: Nehi char 348, 730 ⁇ 732 (1990)]
- GTP-binding proteins and receptors that couple to these GTP-binding proteins play a very important role in signal transduction. Therefore, a peptide having a receptor activity conjugated to a GTP-binding protein present in various organs was found, and its structure and correlation with the GTP-binding protein and the receptor were clarified. Is extremely important in elucidating the causes of physiological phenomena and diseases and in developing pharmaceuticals. For this purpose, it is important to find a DNA encoding a peptide having a receptor activity coupled to a GTP-binding protein, and to enable the cloning of this peptide.
- the present invention has been made in view of the above circumstances, and provides a novel peptide having a receptor activity useful for drug design, and a DNA encoding the peptide.
- conjugated receptor In order to newly identify a peptide having a receptor activity that is conjugated to a GTP-binding protein (hereinafter, referred to as a conjugated receptor), the present inventors have proposed an conjugated receptor that has already been identified. Focusing on the fact that the amino acid sequence has regions of high homology between different conjugated receptors, a polymerase chain using degenerate nucleotide mix primers corresponding to these regions was used. We have found that a new conjugated receptor can be identified using nonreaction (PCR) amplification. Book Based on such a viewpoint, the inventors have identified a novel conjugated receptor and a DNA encoding this conjugated receptor from the cDNA of rat aortic smooth muscle (RASM) cells. That is, the present invention provides a novel peptide having a receptor activity encoded by a DNA containing the nucleotide sequence of SEQ ID NO: 1.
- the present invention provides a novel peptide containing, as a main component, a polypeptide having the amino acid sequence of SEQ ID NO: 2.
- the present invention also provides a DNA encoding a novel peptide having a receptor activity, which comprises the nucleotide sequence of SEQ ID NO: 1.
- a conjugated receptor has a structure as shown in FIG. 1 and has the following features.
- poly (A) + RNA was isolated from RASM cells and synthesized from this poly (A) + R ⁇ 'A.
- a partial cDNA corresponding to the amino acid sequence between the above-mentioned transmembrane domains III and VI is selectively increased by a PCR reaction. This selective PCR amplification is performed using a pair of upstream primer and downstream primer that are presumed to correspond to this partial cDNA.
- the primer used was a digital-enhanced nucleotide mix primer.
- a cDNA library derived from RASM is screened, and cDNA encoding the full length of the conjugated receptor is screened. Obtainable.
- the conjugated receptor of the present invention can be synthesized. That is, an appropriate DNA fragment is synthesized based on the nucleotide sequence of the DNA of the present invention, and the obtained fragment is recloned to an appropriate vector such as a plasmid. Next, the vector is introduced into a microorganism such as E. coli to obtain a transformant. By expressing DNA using this transformant, the conjugated receptor of the present invention can be obtained.
- the distribution of the conjugated receptor of the present invention was determined by isolating mRKA corresponding to the DNA of the present invention from the RNA extracted from various tissues or cells of the rat in accordance with the Northern blotting.
- the conjugated receptor of the present invention was confirmed by performing hybridization using a DNA fragment as a probe. Tar was found to be highly distributed in the heart, lungs, stomach and small intestine.
- the conjugated receptor of the present invention was involved in intimal neovascularization in a murine carotid artery ballooning model created as an arteriosclerosis model of the aortic artery.
- a murine carotid artery ballooning model created as an arteriosclerosis model of the aortic artery.
- increased neovascularization of the injured vascular intima thickens the vascular intima and causes vasoconstriction.
- the expression level of mRNA corresponding to the novel conjugated receptor of the present invention is significantly reduced as compared with healthy endovascular cells. all right.
- the conjugated receptor of the present invention and the DNA encoding the same can be used to investigate the causes of various diseases caused by enhanced angiogenesis in the intima of the blood vessel and to treat these diseases It is extremely useful for designing effective and preventive medicines.
- the DNA of the present invention is a DNA partial region corresponding to a structurally characteristic site of an amino acid sequence common to conjugated receptor pigs such as the transmembrane domain described above. Contains. Using these partial DNAs as primers, new subfamilies of conjugated receptors can be found.
- the DNA encoding the novel peptide having the conjugated receptor activity of the present invention includes all recombinant DNAs, chromosomes, cDNAs, etc., including the nucleotide sequence of SEQ ID NO: 1. You.
- the novel receptor having one activity of the present invention.
- expression of the DNA synthesizes a large amount of a peptide having a receptor activity which co-acts with a GTP-binding protein. be able to.
- This peptide greatly contributes to elucidating the interrelationship between GTP-binding proteins and receptors that couple to GTP-binding proteins.
- physiological phenomena involving this receptor can be achieved.
- it is extremely useful for the design of pharmaceuticals used for treatment and prevention of such diseases.
- FIG. 1 is an explanatory diagram showing the structure of a receptor coupled to a general GTP-binding protein.
- FIG. 2 is an explanatory diagram showing the amino acid sequence of the novel peptide having the receptor activity of the present invention and the nucleotide sequence of DNA encoding the novel peptide.
- FIG. 3 is an explanatory diagram showing the amino acid sequence of the novel peptide having the receptor activity of the present invention and the nucleotide sequence of DNA encoding the novel peptide.
- FIG. 4 is a photograph showing an autoradiograph showing the results of a Northern plot performed to determine the distribution of the novel peptide of the present invention in the examples.
- RNA and preparation of cDNA library were cultured from aortic smooth muscle tissue slices [Expplant method; Chamley-Campbell, J., Champbell, GR, Ross, R. (1972), Physiol. Rev. 59, 1-61], and used from 5 to 10 generations.
- Total RNA was extracted from RASM cells according to the guanidine isocyanate phenol / chloroform extraction method described by Chomczynski, Sacchi, Anal. Biochem. 162, 156-159 (1987). This total RNA was passed twice through a column filled with Oligo dt Cellulose (manufactured by Collaborative Reseach) to purify poly (A) + RNA.
- a cDNA library was synthesized as follows. First, a 5-fold concentrated solution of cDNA synthesis first buffer [250 mM Tris buffer (pH 8.3), 25 mM magnesium chloride, 375 mM potassium chloride] was placed in an eppendorf tube (1.5 ml). , 50mM Jichiosu Rei (manufactured by Boeringer Co., Ltd.) toe Le] ⁇ t, o re-Gore (d T) i 5
- cDNAs larger than O kb were selected. These c DNA collected Ri by the ethanol precipitation, was dissolved in ⁇ 2 0 9 ⁇ i, to this solution, scan subjected to E c 0 RI cut and alkaline phosphate off ⁇ data Ichize process gt10 Phage DNA (Stratagene) 2 ⁇ , ⁇ 4 10-fold concentrated solution of ligase buffer 1 ⁇ I And T4 ligase was added and incubated at 15 ° C. for 16 hours, and the cDNA was ligated to the EcoRI site of; Igt10. A sphage extraction protein solution (manufactured by Stratagene) was added to the fruit, an in vitro package reaction was performed, and library synthesis was completed.
- SM buffer [50 mM Tris buffer (pH 7.5), lOOm sodium chloride, 8 mM magnesium sulfate, 0.01% gelatin] 500 and It was added finely click b chloroform (manufactured by Wako Pure Chemical Industries, Ltd.) 2 0 lambda £, and stored until use at 4 ° C.
- cDNA synthesis primary buffer 8 ⁇ 20.19.5 ⁇ , RNase inhibitor 1-2, deoxynucleotide 4; /, 70 ° C 2 ⁇ g of RASM poly (A) + RNA heat-denatured for 3 min, 0.5 ⁇ t of downstream PCR primer consisting of the nucleotide sequence of SEQ ID NO: 4 and AMV reverse transcriptase 4 /
- the mixture was incubated at 42 ° C for 60 minutes to synthesize the first strand of cDNA.
- the nucleotide sequence of the PCR product subcloned to PUC118 in step (2) was determined by the dideoxy method, and it should be a PCR clone having significant homology to a known conjugated receptor. It was confirmed.
- This PCR clone was subjected to EcoRI treatment to cut out a cDNA insert.
- the probe was obtained by labeling g radioactivity.
- FIGS. 2 and 3 The amino acid sequence of the peptide coded by the cDNA, which is deduced from the base sequence of the cDNA, is also shown in FIGS. 2 and 3.
- the asterisk (*) indicates a laser near the ⁇ ′ end. Glycosylation sites linking with lagins are indicated, and + symbols indicate intracellular loops and phosphorylation sites near the C-terminus. I to VII each represent a transmembrane domain.
- step A (1) the rat cerebrum, cerebellum, heart, lung, liver, spleen, stomach, and small intestine 5 g of poly (A) + RNA obtained from smooth muscle cells (A10) derived from kidney, adrenal gland, testis, skeletal muscle, aorta, RASM and rat fetal aorta, ⁇ g was electrophoresed on a 1% agarose gel supplemented with formaldehyde at 80 V for 3 hours. After this, the RNA was transferred from the gel to a nylon membrane.
- the BamHI to Ec0RV1.3 kb fragment of the AGR16 cDNA obtained in step A (3) was converted into a fragment according to the same procedure as the method shown in step A (3). [.
- the probe was obtained by labeling with — 32 P] d CTP.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94906370A EP0643076A4 (en) | 1993-02-10 | 1994-02-10 | NOVEL PEPTIDE HAVING RECEPTOR ACTIVITY AND DNA ENCODING THE PEPTIDE. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4433093A JPH06234797A (ja) | 1993-02-10 | 1993-02-10 | レセプター活性を有する新規ペプチドおよび該ペプチドをコードするdna |
JP5/44330 | 1993-02-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994018237A1 true WO1994018237A1 (en) | 1994-08-18 |
Family
ID=12688504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/000202 WO1994018237A1 (en) | 1993-02-10 | 1994-02-10 | Novel peptide having receptor activity and dna coding for said peptide |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0643076A4 (ja) |
JP (1) | JPH06234797A (ja) |
WO (1) | WO1994018237A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874245A (en) * | 1996-05-16 | 1999-02-23 | Takeda Chemical Industries, Ltd. | Human G-protein coupled receptor (HIBCD07) |
JP2002512016A (ja) * | 1998-04-23 | 2002-04-23 | スミスクライン ビーチャム コーポレーション | Edgファミリー遺伝子、ヒトh218 |
GB9923890D0 (en) * | 1999-10-08 | 1999-12-08 | Pfizer Ltd | Novel polypeptide |
US20040048263A1 (en) * | 2000-06-14 | 2004-03-11 | Masanori Miwa | Novel g protein-coupled receptor protein and dna thereof |
US7511159B2 (en) | 2003-12-25 | 2009-03-31 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
PT2762466T (pt) | 2011-09-29 | 2017-07-31 | Ono Pharmaceutical Co | Derivado de fenilo |
EP2980072B1 (en) | 2013-03-26 | 2018-04-25 | ONO Pharmaceutical Co., Ltd. | Phenyl derivative |
JP6264134B2 (ja) | 2013-03-26 | 2018-01-24 | 小野薬品工業株式会社 | フェニル誘導体を含有する医薬 |
-
1993
- 1993-02-10 JP JP4433093A patent/JPH06234797A/ja active Pending
-
1994
- 1994-02-10 WO PCT/JP1994/000202 patent/WO1994018237A1/ja not_active Application Discontinuation
- 1994-02-10 EP EP94906370A patent/EP0643076A4/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
Biochem. Biophys. Res. Commun., Vol. 190, No. 3, 1993, H. OKAZAKI et al., "Molecular Cloning of a Novel Putative G Protein-Coupled Receptor Expressed in the Cardio Vascular System", p. 1104-9. * |
Cell, Vol. 64, No. 6, 1990, SHAUN R. COUGHLIN et al., "Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation", p. 1057-1068. * |
See also references of EP0643076A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP0643076A1 (en) | 1995-03-15 |
EP0643076A4 (en) | 1995-09-27 |
JPH06234797A (ja) | 1994-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goraczniak et al. | Structural and functional characterization of the rod outer segment membrane guanylate cyclase | |
Gantz et al. | Cloning and chromosomal localization of a gene (GPR18) encoding a novel seven transmembrane receptor highly expressed in spleen and testis | |
Wu et al. | Cloning and expression of the cDNA for human γ-glutamyl carboxylase | |
US5237051A (en) | Purified enterotoxin receptor protein | |
Lowe et al. | Human atrial natriuretic peptide receptor defines a new paradigm for second messenger signal transduction. | |
JP2002512524A (ja) | 膜貫通ドメインを有するヒト蛋白質及びそれをコードするdna | |
CN107636154A (zh) | 促滤泡素抑制素相关的融合蛋白及其用途 | |
NZ257631A (en) | Serine/threonine kinase domain-containing protein, dna and hosts therefor | |
NO324775B1 (no) | Renset peptid, isolert nukleinsyresekvens og deres anvendelse. | |
WO1994018237A1 (en) | Novel peptide having receptor activity and dna coding for said peptide | |
Islam et al. | Isolation and characterization of vascular smooth muscle inositol 1, 4, 5-trisphosphate receptor | |
JP2005503106A (ja) | 分泌タンパク質 | |
Kashiwagi et al. | Cloning, properties and tissue distribution of natriuretic peptide receptor‐A of euryhaline eel, Anguilla japonica | |
JP2002505577A (ja) | Smad相互作用ポリペプチド及びそれらの使用 | |
JP2004500870A (ja) | 分泌タンパク質 | |
JPH08502737A (ja) | セロトニン作動性レセプター活性を有するポリペプチド(5ht2c)及び利用 | |
DE69535590T2 (de) | Für den bradykinin-b1-rezeptor kodierende dna | |
Oka et al. | Primary structure of rat liver mannan-binding protein deduced from its cDNA sequence | |
JP2000516442A (ja) | ヒト膜抗原tm4スーパーファミリー蛋白質およびそれをコードするdna | |
JP2004530409A (ja) | 膜貫通タンパク質 | |
CA2423704A1 (en) | G-protein coupled receptors | |
US6416972B1 (en) | DNA encoding a prostaglandin F2α receptor, a host cell transformed therewith and an expression product thereof | |
US6627733B2 (en) | Receptor tyrosine kinase with a discoidin-type binding domain | |
WO2000031256A1 (fr) | Nouveau gene codant une proteine membranaire specifique au cerveau | |
Owman et al. | Molecular cloning and tissue distribution of cDNA encoding a novel chemoattractant-like receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1994 318656 Date of ref document: 19941011 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994906370 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994906370 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994906370 Country of ref document: EP |